Aging Expert Heading FDA Could be Good for Antiaging Projects

In April, aging research expert Norman E. (Ned) Sharpless, MD will become the acting commissioner of the Food and Drug Administration. Dr. Sharpless is a 2003 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar. Ned served on AFAR’s National Scientific Advisory Council from 2005-2011 and chaired the Selection Committee of the Glenn/AFAR Postdoctoral Program for Transnational Research on Aging program in 2015 and 2016. For over 30 years, AFAR has supported the science of healthier aging.

Metforming Aging Trial

AFAR has raised $35 million out of a needed $55 million for the Targeting Aging with Metformin Trial. There would still be the need for the NIH (National Institute of Health) to contribute another $40 million for the study. Dr. Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine, designed the Targeting Aging with Metformin anti-aging study. Metformin is an antidiabetic drug that was approved by the FDA more than 70 years ago. It is estimated that 120 million people take metformin. It has been shown to extend the lives of nematodes by 57% and mice by 6%. TAME will consist of 3,000 patients between 65 – 79 years old and have a composite primary endpoint of myocardial infarction, stroke, heart failure, cancer, dementia and death. The trial could detect 22.5% reduced incidences of those diseases.
SOURCES- AFAR, New York Times, FDA, Nature Written By Brian Wang, Nextbigfuture

Subscribe on Google News